SI1176964T1 - Uporaba et743 za zdravljenje raka - Google Patents

Uporaba et743 za zdravljenje raka

Info

Publication number
SI1176964T1
SI1176964T1 SI200030905T SI200030905T SI1176964T1 SI 1176964 T1 SI1176964 T1 SI 1176964T1 SI 200030905 T SI200030905 T SI 200030905T SI 200030905 T SI200030905 T SI 200030905T SI 1176964 T1 SI1176964 T1 SI 1176964T1
Authority
SI
Slovenia
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
SI200030905T
Other languages
English (en)
Slovenian (sl)
Inventor
Angela Dept Of Clinical Bowman
Esteban Cvitkovic
George Daniel Dept Of Demetri
Cecilia Pharma Mar S A Guzman
Jose Pharma Mar S A Jimeno
Lazaro Luis Pharma Mar S Lopez
Jean Louis Service D On Misset
C Uni Of Glasgow Crc B Twelves
Hoff Daniel D Arizona Canc Von
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of SI1176964T1 publication Critical patent/SI1176964T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200030905T 1999-05-13 2000-05-15 Uporaba et743 za zdravljenje raka SI1176964T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
PCT/GB2000/001857 WO2000069441A1 (en) 1999-05-13 2000-05-15 Compositions and uses of et743 for treating cancer

Publications (1)

Publication Number Publication Date
SI1176964T1 true SI1176964T1 (sl) 2007-02-28

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200030905T SI1176964T1 (sl) 1999-05-13 2000-05-15 Uporaba et743 za zdravljenje raka
SI200030977T SI1702618T1 (sl) 1999-05-13 2000-05-15 Uporaba et743 v kombinirani terapiji z deksametazonom za zdravljenje raka
SI200031067T SI1716853T1 (sl) 1999-05-13 2000-05-15 Zdravljenje rakov äśloveĺ kega telesa z uporabo et743

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200030977T SI1702618T1 (sl) 1999-05-13 2000-05-15 Uporaba et743 v kombinirani terapiji z deksametazonom za zdravljenje raka
SI200031067T SI1716853T1 (sl) 1999-05-13 2000-05-15 Zdravljenje rakov äśloveĺ kega telesa z uporabo et743

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1716853B9 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN1360503A (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE500830T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE122008000013I1 (enExample)
DK (3) DK1176964T3 (enExample)
ES (2) ES2272279T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1176964E (enExample)
SI (3) SI1176964T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EA005564B1 (ru) * 2000-11-06 2005-04-28 Фарма Мар, С.А. Эффективные противоопухолевые лекарственные средства
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
MX2008014404A (es) * 2006-05-12 2008-11-27 Pharma Mar Sa Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
AU2017215603A1 (en) * 2016-02-04 2018-08-09 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and method for manufacturing the same
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
BR112022020812A2 (pt) 2020-04-15 2022-11-29 Ever Valinject Gmbh Composição farmacêutica compreendendo trabectedina e um aminoacido, formulação liofilizada e uma solução de injeção intravenosa compreendendo dita composição
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
AU2022277799A1 (en) * 2021-05-19 2023-12-21 Pharma Mar, S.A. Dosage regimens for ecubectedin
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
AU589282B2 (en) * 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69734290T2 (de) * 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
CZ301083B6 (cs) 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
KR100643092B1 (ko) * 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
EA005564B1 (ru) 2000-11-06 2005-04-28 Фарма Мар, С.А. Эффективные противоопухолевые лекарственные средства
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN1897949A (zh) 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
AU2005261860A1 (en) 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RU2359700C2 (ru) 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
MX2008014404A (es) 2006-05-12 2008-11-27 Pharma Mar Sa Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.

Also Published As

Publication number Publication date
DE60030554D1 (de) 2006-10-19
DK1176964T3 (da) 2007-01-15
DE60036826D1 (de) 2007-11-29
SI1716853T1 (sl) 2011-10-28
MXPA01011562A (es) 2002-07-30
DE60036826T2 (de) 2008-08-28
DE60030554T2 (de) 2007-09-13
BG106171A (en) 2002-06-28
HU229866B1 (en) 2014-10-28
DK1716853T3 (da) 2011-06-27
CY2008007I2 (el) 2009-11-04
SI1702618T1 (sl) 2008-02-29
AU2005200180B9 (en) 2008-05-29
EP1176964A1 (en) 2002-02-06
LU91418I9 (enExample) 2019-01-02
CY1105818T1 (el) 2011-02-02
UA74782C2 (uk) 2006-02-15
IL146434A0 (en) 2002-07-25
ATE375795T1 (de) 2007-11-15
NO20015516D0 (no) 2001-11-12
AU777417B2 (en) 2004-10-14
US20070275942A1 (en) 2007-11-29
MY164077A (en) 2017-11-30
CZ20014081A3 (cs) 2002-11-13
FR08C0013I1 (enExample) 2008-05-30
EP1176964B1 (en) 2006-09-06
FR08C0013I2 (fr) 2009-10-30
CY1112753T1 (el) 2016-02-10
BR0010531A (pt) 2002-06-04
EP1716853A2 (en) 2006-11-02
DE60045720D1 (de) 2011-04-21
DK1702618T3 (da) 2008-02-25
DE60030554T8 (de) 2008-01-10
IL146434A (en) 2008-03-20
CY1107143T1 (el) 2010-07-28
NL300337I1 (nl) 2008-05-01
NL300337I2 (nl) 2008-09-01
SK287580B6 (sk) 2011-03-04
ATE500830T1 (de) 2011-03-15
JP5777562B2 (ja) 2015-09-09
EP1716853B1 (en) 2011-03-09
AU4597500A (en) 2000-12-05
ES2272279T3 (es) 2007-05-01
EP1716853A3 (en) 2006-11-15
KR20020019914A (ko) 2002-03-13
AR028476A1 (es) 2003-05-14
EP1716853B9 (en) 2011-09-28
AU2005200180A1 (en) 2005-02-10
DE122008000013I1 (de) 2008-08-07
CY2008007I1 (el) 2009-11-04
CA2373794C (en) 2005-10-11
EP1702618B1 (en) 2007-10-17
AU2005200180B2 (en) 2007-12-13
JP2012149095A (ja) 2012-08-09
LU91418I2 (fr) 2008-05-13
PT1716853E (pt) 2011-05-12
ATE338552T1 (de) 2006-09-15
WO2000069441A1 (en) 2000-11-23
US8119638B2 (en) 2012-02-21
HUP0201187A2 (en) 2002-09-28
CN1360503A (zh) 2002-07-24
CN1679631A (zh) 2005-10-12
PL198185B1 (pl) 2008-06-30
JP2002544231A (ja) 2002-12-24
CN100477993C (zh) 2009-04-15
NO20015516L (no) 2002-01-11
NZ515423A (en) 2004-04-30
CA2373794A1 (en) 2000-11-23
PT1702618E (pt) 2008-01-11
PL352931A1 (en) 2003-09-22
TR200103819T2 (tr) 2002-04-22
CZ301482B6 (cs) 2010-03-17
HUP0201187A3 (en) 2002-11-28
BG65680B1 (bg) 2009-06-30
NO2008005I1 (no) 2008-06-09
ES2294756T3 (es) 2008-04-01
HUS1500001I1 (hu) 2016-08-29
SK16442001A3 (sk) 2002-03-05
EP1702618A2 (en) 2006-09-20
PT1176964E (pt) 2007-01-31
EP1176964B8 (en) 2007-10-10
EP1702618A3 (en) 2006-12-27
NO2008005I2 (enExample) 2010-09-27
NO324564B1 (no) 2007-11-19

Similar Documents

Publication Publication Date Title
EP1176964B8 (en) Uses of et743 for treating cancer
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU8322401A (en) Indole compounds useful for the treatment of cancer
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
GB9929972D0 (en) Hair treatment composition
AU7636800A (en) Improved ricin-like toxins for treatment of cancer
IL149281A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
GB9819999D0 (en) Treatment of cancer
GB0026015D0 (en) Cancer treatment
HRP20020262B1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
PL353769A1 (en) Chemically-stabilized chlorite solutions for treating cancer
GB9804361D0 (en) Cancer treatment
AU1036801A (en) Agent for treating cephalic pain
AU4598100A (en) Treating cancer
GB9903035D0 (en) Treating cancer
GB9911183D0 (en) Treatment of cancers
GB2334579B (en) Treating cancer
GB9914971D0 (en) Treating cancer
GB0007254D0 (en) Treating cancer
GB9908176D0 (en) Cancer treatment
GB9927106D0 (en) Cancer treatment
GB9918534D0 (en) Treatment of cancers
GB9911346D0 (en) Treatment of cancers